



Clinical trial results:

A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B-cell Lymphoma

Summary

EudraCT number	2011-001616-57
Trial protocol	BE DE
Global end of trial date	12 September 2014

Results information

Result version number	v1 (current)
This version publication date	24 March 2016
First version publication date	24 March 2016

Trial information

Trial identification

Sponsor protocol code	ARD12130
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01403636
WHO universal trial number (UTN)	U1111-1118-6417

Notes:

Sponsors

Sponsor organisation name	Sanofi aventis recherche & développement
Sponsor organisation address	1 avenue Pierre Brossolette, Chilly-Mazarin, France, 91380
Public contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact- US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact- US@sanofi.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 December 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 September 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of SAR245409 as determined by the objective response rate (ORR) in subjects with one of the following relapsed or refractory (R/R) lymphoma or leukemia subtypes: mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or diffuse large B cell lymphoma (DLBCL).

Protection of trial subjects:

Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency. Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 October 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 10
Country: Number of subjects enrolled	United States: 81
Country: Number of subjects enrolled	Netherlands: 14
Country: Number of subjects enrolled	Belgium: 18
Country: Number of subjects enrolled	France: 30
Country: Number of subjects enrolled	Germany: 14
Worldwide total number of subjects	167
EEA total number of subjects	76

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	62
From 65 to 84 years	102
85 years and over	3

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 30 centers in 6 countries. A total of 167 subjects were enrolled between 19 October 2011 and 24 July 2013.

Pre-assignment

Screening details:

All enrolled subjects were treated.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	SAR245409: R/R MCL Subjects

Arm description:

Subjects with R/R MCL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, serious adverse event [SAE] requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Arm type	Experimental
Investigational medicinal product name	SAR245409
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

SAR245409 50 mg twice daily (BID)

Arm title	SAR245409: R/R FL Subjects
------------------	----------------------------

Arm description:

Subjects with R/R Grade 1, 2 or 3a FL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Arm type	Experimental
Investigational medicinal product name	SAR245409
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

SAR245409 50 mg BID

Arm title	SAR245409: R/R CLL/SLL Subjects
------------------	---------------------------------

Arm description:

Subjects with R/R CLL/SLL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	SAR245409
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use
Dosage and administration details: SAR245409 50 mg BID	
Arm title	SAR245409: R/R DLBCL Subjects

Arm description:

Subjects with R/R DLBCL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Arm type	Experimental
Investigational medicinal product name	SAR245409
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use
Dosage and administration details: SAR245409 50 mg BID	

Number of subjects in period 1	SAR245409: R/R MCL Subjects	SAR245409: R/R FL Subjects	SAR245409: R/R CLL/SLL Subjects
Started	42	47	36
Completed	0	0	0
Not completed	42	47	36
Other than specified above	-	4	2
Disease progression	31	20	24
Roll over to the treatment extension study	2	12	1
Adverse Event	8	11	9
Poor compliance to protocol	1	-	-

Number of subjects in period 1	SAR245409: R/R DLBCL Subjects
Started	42
Completed	0
Not completed	42
Other than specified above	2
Disease progression	32
Roll over to the treatment extension study	3
Adverse Event	5
Poor compliance to protocol	-

Baseline characteristics

Reporting groups

Reporting group title	SAR245409: R/R MCL Subjects
-----------------------	-----------------------------

Reporting group description:

Subjects with R/R MCL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, serious adverse event [SAE] requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Reporting group title	SAR245409: R/R FL Subjects
-----------------------	----------------------------

Reporting group description:

Subjects with R/R Grade 1, 2 or 3a FL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Reporting group title	SAR245409: R/R CLL/SLL Subjects
-----------------------	---------------------------------

Reporting group description:

Subjects with R/R CLL/SLL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Reporting group title	SAR245409: R/R DLBCL Subjects
-----------------------	-------------------------------

Reporting group description:

Subjects with R/R DLBCL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Reporting group values	SAR245409: R/R MCL Subjects	SAR245409: R/R FL Subjects	SAR245409: R/R CLL/SLL Subjects
Number of subjects	42	47	36
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	69.9 ± 9.4	63.3 ± 12.2	68.6 ± 7.8
Gender categorical Units: Subjects			
Female	9	20	10
Male	33	27	26

Reporting group values	SAR245409: R/R DLBCL Subjects	Total	
Number of subjects	42	167	
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	64.2 ± 13.5	-	
Gender categorical Units: Subjects			
Female	14	53	

Male	28	114	
------	----	-----	--

End points

End points reporting groups

Reporting group title	SAR245409: R/R MCL Subjects
Reporting group description: Subjects with R/R MCL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, serious adverse event [SAE] requiring treatment discontinuation, consent withdrawal or lost to follow-up).	
Reporting group title	SAR245409: R/R FL Subjects
Reporting group description: Subjects with R/R Grade 1, 2 or 3a FL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).	
Reporting group title	SAR245409: R/R CLL/SLL Subjects
Reporting group description: Subjects with R/R CLL/SLL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).	
Reporting group title	SAR245409: R/R DLBCL Subjects
Reporting group description: Subjects with R/R DLBCL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).	

Primary: Percentage of Subjects with Objective Response (OR)

End point title	Percentage of Subjects with Objective Response (OR) ^[1]
End point description: Modified revised IWRC criteria- MCL, FL, DLBCL and SLL=complete response (CR), unconfirmed CR (CRu) or partial response (PR). CR: disappearance of all evidence of disease. CRu: CR with indeterminate bone marrow (BM) histology or >75% decrease from baseline (BL) in SPD of all measurable lesions but with residual mass. PR: Regression of measurable disease and no new sites. Modified IWCLL criteria-CLL=CR, incomplete marrow recovery [CRi], nodular PR [nPR] or PR. CR: no lymphadenopathy (Ly)/ hepatomegaly/ splenomegaly/ constitutional symptoms; neutrophils >1500/μL, platelets (PL) >100000/μL, Hb >11 g/dL, lymphocytes (LC) <4000/μL, BM sample is normocellular for age, <30% LC, no lymphoid nodule. PR: ≥50% decrease in LC, Ly, size of liver and spleen and one of following results: PL >100000/μL or 50% improvement over BL, Hb >11 g/dL or 50% improvement over BL, LC <4000/μL. Efficacy population: subjects who received at least 2 cycles with baseline and at least 1 post-baseline tumor assessment.	
End point type	Primary
End point timeframe: Baseline; At the end of Cycle 2 following the first dose of investigational medicinal product (IMP), and then every 3 cycles for a period of 2 years or until disease progression or withdrawal from study	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Since analysis is descriptive in nature, statistical data could not be provided.

End point values	SAR245409: R/R MCL Subjects	SAR245409: R/R FL Subjects	SAR245409: R/R CLL/SLL Subjects	SAR245409: R/R DLBCL Subjects
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	46	35	41
Units: Percentage of Subjects				
number (confidence interval 95%)	11.9 (4 to 25.6)	41.3 (27 to 56.8)	11.4 (3.2 to 26.7)	4.9 (0.6 to 16.5)

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
-----------------	---------------------------------

End point description:

PFS was defined as time (days) from start of treatment to the date of progression or death regardless of cause. Actual dates of tumor assessments were used for this calculation. If death or progression was not observed, data on PFS was censored at date of last tumor assessment without evidence of progression. Data after initiation of subsequent anticancer therapy was not used for endpoint. PFS was estimated using Kaplan-Meier method. Disease progression was defined as one of following: Lymphadenopathy; increase in liver or spleen size by 50% or more or de novo appearance of hepatomegaly or splenomegaly; increase in number of blood lymphocytes by 50% or more with at least 5000 B lymphocytes per μ L; transformation to a more aggressive histology (eg, Richter syndrome); Occurrence of cytopenia (neutropenia, anemia, or thrombocytopenia) attributable to CLL. Analysis was performed on efficacy population. In this section, '99999' represents data not calculated for maximum range of median.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; at the end of Cycle 2 following the first dose of IMP, and then every 3 cycles for a period of 2 years or until disease progression or withdrawal from study

End point values	SAR245409: R/R MCL Subjects	SAR245409: R/R FL Subjects	SAR245409: R/R CLL/SLL Subjects	SAR245409: R/R DLBCL Subjects
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	46	35	41
Units: Weeks				
median (full range (min-max))	8.9 (7.86 to 12.86)	58 (26 to 99999)	24.1 (16.57 to 31.57)	7.1 (5.14 to 8.14)

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival at 6 Months

End point title	Progression Free Survival at 6 Months
-----------------	---------------------------------------

End point description:

PFS was estimated using the Kaplan-Meier method as defined in the previous endpoint. Analysis was

performed on efficacy population.

End point type	Secondary
End point timeframe:	
6 months	

End point values	SAR245409: R/R MCL Subjects	SAR245409: R/R FL Subjects	SAR245409: R/R CLL/SLL Subjects	SAR245409: R/R DLBCL Subjects
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	46	35	41
Units: Percentage of Subjects				
number (not applicable)	21.4	54.3	45.7	7.3

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Cycle 13 and beyond [maximum exposure: 128 weeks for some subjects]) regardless of seriousness or relationship to investigational product.

Adverse event reporting additional description:

Reported adverse events and death are treatment-emergent that is AEs that developed/worsened and death that occurred during the 'on treatment period' (within 30 days from the last dose of SAR245409).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

Reporting groups

Reporting group title	SAR245409: R/R MCL Subjects
-----------------------	-----------------------------

Reporting group description:

Subjects with R/R MCL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Reporting group title	SAR245409: R/R FL Subjects
-----------------------	----------------------------

Reporting group description:

Subjects with R/R Grade 1, 2 or 3a FL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Reporting group title	SAR245409: R/R CLL/SLL Subjects
-----------------------	---------------------------------

Reporting group description:

Subjects with R/R CLL/SLL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Reporting group title	SAR245409: R/R DLBCL Subjects
-----------------------	-------------------------------

Reporting group description:

Subjects with R/R DLBCL received SAR245409 for 28-day continuous dosing cycle until withdrawal criteria met (until disease progression, unacceptable toxicity, SAE requiring treatment discontinuation, consent withdrawal or lost to follow-up).

Serious adverse events	SAR245409: R/R MCL Subjects	SAR245409: R/R FL Subjects	SAR245409: R/R CLL/SLL Subjects
Total subjects affected by serious adverse events			
subjects affected / exposed	23 / 42 (54.76%)	25 / 47 (53.19%)	27 / 36 (75.00%)
number of deaths (all causes)	8	3	7
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Leukaemic Infiltration Pulmonary			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Malignant Neoplasm Of Orbit			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Richter's Syndrome			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Squamous Cell Carcinoma Of Skin			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic Stenosis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Deep Vein Thrombosis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior Vena Cava Syndrome			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Medical Device Removal			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Catheter Site Oedema			

subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Discomfort			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease Progression			
subjects affected / exposed	3 / 42 (7.14%)	1 / 47 (2.13%)	2 / 36 (5.56%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 1
Fatigue			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General Physical Health Deterioration			
subjects affected / exposed	4 / 42 (9.52%)	1 / 47 (2.13%)	3 / 36 (8.33%)
occurrences causally related to treatment / all	1 / 4	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Malaise			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	3 / 42 (7.14%)	3 / 47 (6.38%)	3 / 36 (8.33%)
occurrences causally related to treatment / all	0 / 4	1 / 3	1 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute Respiratory Distress Syndrome			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute Respiratory Failure			

subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchostenosis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 42 (0.00%)	3 / 47 (6.38%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural Effusion			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Aspiration			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Embolism			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Haemorrhage			

subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Respiratory Failure			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	3 / 36 (8.33%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Stridor			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	0 / 42 (0.00%)	2 / 47 (4.26%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate Aminotransferase Increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood Creatinine Increased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
C-Reactive Protein Increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen Saturation Decreased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Transaminases Increased			

subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental Overdose			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional Overdose			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Thoracic Procedure Complication			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural Haematoma			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute Myocardial Infarction			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina Pectoris			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Atrial Fibrillation			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac Failure Congestive			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-Respiratory Arrest			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Left Ventricular Dysfunction			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right Ventricular Failure			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular Accident			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depressed Level Of Consciousness			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune Haemolytic Anaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile Neutropenia			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	3 / 36 (8.33%)
occurrences causally related to treatment / all	0 / 1	1 / 3	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Age-Related Macular Degeneration			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Abdominal Pain			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Abdominal Pain Upper			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal Fissure			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 42 (2.38%)	2 / 47 (4.26%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum Intestinal			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal Reflux Disease			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal Haemorrhage			

subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash Macular			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic Skin Eruption			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal Failure			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Renal Failure Acute			
subjects affected / exposed	1 / 42 (2.38%)	2 / 47 (4.26%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypercalcaemia Of Malignancy			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back Pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral Disc Protrusion			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metatarsalgia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical Pneumonia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			

subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus Infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device Related Infection			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile Infection			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fungaemia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes Zoster			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Histoplasmosis Disseminated			

subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	2 / 36 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised Infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung Infection			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ophthalmic Herpes Zoster			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	4 / 42 (9.52%)	5 / 47 (10.64%)	3 / 36 (8.33%)
occurrences causally related to treatment / all	0 / 4	0 / 6	1 / 3
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pneumonia Haemophilus			

subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Pneumococcal			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Staphylococcal			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	2 / 42 (4.76%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Septic Shock			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft Tissue Infection			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheobronchitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper Respiratory Tract Infection			

subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection Pseudomonal			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes Mellitus			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure To Thrive			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			

subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophosphataemia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour Lysis Syndrome			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	SAR245409: R/R DLBCL Subjects		
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 42 (52.38%)		
number of deaths (all causes)	6		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Leukaemic Infiltration Pulmonary			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant Neoplasm Of Orbit			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Richter's Syndrome			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous Cell Carcinoma Of Skin			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Vascular disorders			
Aortic Stenosis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Deep Vein Thrombosis			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Superior Vena Cava Syndrome			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Medical Device Removal			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Catheter Site Oedema			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Discomfort			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Disease Progression			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 3		
Fatigue			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General Physical Health Deterioration			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Malaise			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute Respiratory Distress Syndrome			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute Respiratory Failure			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchostenosis			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Epistaxis			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural Effusion			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia Aspiration			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumothorax			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary Embolism			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary Haemorrhage			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory Failure			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stridor			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Alanine Aminotransferase Increased			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aspartate Aminotransferase Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood Creatinine Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
C-Reactive Protein Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oxygen Saturation Decreased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transaminases Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Accidental Overdose			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intentional Overdose			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Laceration			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative Thoracic Procedure Complication			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subdural Haematoma			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute Myocardial Infarction			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Angina Pectoris			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial Fibrillation			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac Failure Congestive			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardio-Respiratory Arrest			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Left Ventricular Dysfunction			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Right Ventricular Failure			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular Accident			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Depressed Level Of Consciousness			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Autoimmune Haemolytic Anaemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile Neutropenia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenopathy			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Age-Related Macular Degeneration			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cataract			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal Pain Upper			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal Fissure			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			

subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulum Intestinal				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dyspepsia				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Gastritis				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrooesophageal Reflux Disease				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemorrhoidal Haemorrhage				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vomiting				

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash Macular			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toxic Skin Eruption			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal Failure			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Renal Failure Acute			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Endocrine disorders			
Hypercalcaemia Of Malignancy			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back Pain			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intervertebral Disc Protrusion			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metatarsalgia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical Pneumonia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cytomegalovirus Infection			

subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Device Related Infection				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Febrile Infection				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fungaemia				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes Zoster				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Histoplasmosis Disseminated				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Localised Infection				

subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung Infection				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mastoiditis				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ophthalmic Herpes Zoster				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	4 / 42 (9.52%)			
occurrences causally related to treatment / all	1 / 4			
deaths causally related to treatment / all	0 / 0			
Pneumonia Haemophilus				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia Pneumococcal				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia Staphylococcal				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sepsis				

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Septic Shock			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinusitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Soft Tissue Infection			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tracheobronchitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary Tract Infection Pseudomonal			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dehydration			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetes Mellitus			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Failure To Thrive			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypercalcaemia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypophosphataemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tumour Lysis Syndrome			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	SAR245409: R/R MCL Subjects	SAR245409: R/R FL Subjects	SAR245409: R/R CLL/SLL Subjects
Total subjects affected by non-serious adverse events			
subjects affected / exposed	39 / 42 (92.86%)	43 / 47 (91.49%)	35 / 36 (97.22%)
Vascular disorders			
Deep Vein Thrombosis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences (all)	0	0	2
Hypertension			
subjects affected / exposed	3 / 42 (7.14%)	4 / 47 (8.51%)	4 / 36 (11.11%)
occurrences (all)	4	4	4
Hypotension			
subjects affected / exposed	0 / 42 (0.00%)	2 / 47 (4.26%)	3 / 36 (8.33%)
occurrences (all)	0	3	3
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 42 (9.52%)	8 / 47 (17.02%)	3 / 36 (8.33%)
occurrences (all)	5	8	3
Chills			
subjects affected / exposed	2 / 42 (4.76%)	5 / 47 (10.64%)	5 / 36 (13.89%)
occurrences (all)	2	6	6
Fatigue			
subjects affected / exposed	14 / 42 (33.33%)	14 / 47 (29.79%)	9 / 36 (25.00%)
occurrences (all)	17	17	9
General Physical Health Deterioration			
subjects affected / exposed	4 / 42 (9.52%)	0 / 47 (0.00%)	3 / 36 (8.33%)
occurrences (all)	4	0	3
Influenza Like Illness			
subjects affected / exposed	1 / 42 (2.38%)	2 / 47 (4.26%)	2 / 36 (5.56%)
occurrences (all)	1	2	2
Malaise			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences (all)	0	0	2
Non-Cardiac Chest Pain			

subjects affected / exposed	1 / 42 (2.38%)	2 / 47 (4.26%)	2 / 36 (5.56%)
occurrences (all)	1	2	2
Oedema Peripheral			
subjects affected / exposed	8 / 42 (19.05%)	2 / 47 (4.26%)	6 / 36 (16.67%)
occurrences (all)	10	3	6
Pyrexia			
subjects affected / exposed	10 / 42 (23.81%)	9 / 47 (19.15%)	13 / 36 (36.11%)
occurrences (all)	14	19	19
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	10 / 42 (23.81%)	10 / 47 (21.28%)	10 / 36 (27.78%)
occurrences (all)	10	10	14
Dysphonia			
subjects affected / exposed	2 / 42 (4.76%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences (all)	2	0	2
Dyspnoea			
subjects affected / exposed	7 / 42 (16.67%)	5 / 47 (10.64%)	10 / 36 (27.78%)
occurrences (all)	7	5	17
Dyspnoea Exertional			
subjects affected / exposed	1 / 42 (2.38%)	3 / 47 (6.38%)	1 / 36 (2.78%)
occurrences (all)	1	3	1
Epistaxis			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	4 / 36 (11.11%)
occurrences (all)	1	1	4
Lung Infiltration			
subjects affected / exposed	1 / 42 (2.38%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences (all)	1	0	2
Oropharyngeal Pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	4 / 36 (11.11%)
occurrences (all)	0	0	4
Pleural Effusion			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	3 / 36 (8.33%)
occurrences (all)	0	0	5
Productive Cough			

subjects affected / exposed	2 / 42 (4.76%)	2 / 47 (4.26%)	3 / 36 (8.33%)
occurrences (all)	3	2	3
Wheezing			
subjects affected / exposed	0 / 42 (0.00%)	2 / 47 (4.26%)	2 / 36 (5.56%)
occurrences (all)	0	2	3
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	2 / 36 (5.56%)
occurrences (all)	0	1	2
Depression			
subjects affected / exposed	1 / 42 (2.38%)	2 / 47 (4.26%)	2 / 36 (5.56%)
occurrences (all)	1	2	2
Insomnia			
subjects affected / exposed	0 / 42 (0.00%)	3 / 47 (6.38%)	5 / 36 (13.89%)
occurrences (all)	0	3	5
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	2 / 42 (4.76%)	4 / 47 (8.51%)	8 / 36 (22.22%)
occurrences (all)	3	6	9
Amylase Increased			
subjects affected / exposed	2 / 42 (4.76%)	1 / 47 (2.13%)	2 / 36 (5.56%)
occurrences (all)	2	2	5
Aspartate Aminotransferase Increased			
subjects affected / exposed	3 / 42 (7.14%)	2 / 47 (4.26%)	4 / 36 (11.11%)
occurrences (all)	4	3	4
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	1 / 42 (2.38%)	2 / 47 (4.26%)	5 / 36 (13.89%)
occurrences (all)	2	2	6
Blood Creatinine Increased			
subjects affected / exposed	4 / 42 (9.52%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences (all)	6	0	3
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	2 / 42 (4.76%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences (all)	2	0	2
C-Reactive Protein Increased			

subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	3 / 36 (8.33%) 4
Gamma-Glutamyltransferase Increased subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 47 (0.00%) 0	5 / 36 (13.89%) 5
Platelet Count Decreased subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3	1 / 47 (2.13%) 1	4 / 36 (11.11%) 4
Weight Decreased subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 6	7 / 47 (14.89%) 8	6 / 36 (16.67%) 6
White Blood Cell Count Decreased subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 5	4 / 47 (8.51%) 5	0 / 36 (0.00%) 0
Injury, poisoning and procedural complications Tendon Rupture subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	2 / 36 (5.56%) 2
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	2 / 36 (5.56%) 2
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	2 / 47 (4.26%) 2	2 / 36 (5.56%) 2
Dysgeusia subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	4 / 47 (8.51%) 4	1 / 36 (2.78%) 1
Headache subjects affected / exposed occurrences (all)	10 / 42 (23.81%) 13	7 / 47 (14.89%) 10	5 / 36 (13.89%) 5
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 8	3 / 47 (6.38%) 4	12 / 36 (33.33%) 23

Leukocytosis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	3 / 36 (8.33%)
occurrences (all)	0	1	3
Leukopenia			
subjects affected / exposed	1 / 42 (2.38%)	2 / 47 (4.26%)	2 / 36 (5.56%)
occurrences (all)	1	2	2
Lymphopenia			
subjects affected / exposed	0 / 42 (0.00%)	4 / 47 (8.51%)	1 / 36 (2.78%)
occurrences (all)	0	6	1
Neutropenia			
subjects affected / exposed	3 / 42 (7.14%)	5 / 47 (10.64%)	5 / 36 (13.89%)
occurrences (all)	3	6	9
Thrombocytopenia			
subjects affected / exposed	3 / 42 (7.14%)	4 / 47 (8.51%)	8 / 36 (22.22%)
occurrences (all)	4	7	16
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	6 / 42 (14.29%)	3 / 47 (6.38%)	4 / 36 (11.11%)
occurrences (all)	7	3	5
Abdominal Pain Upper			
subjects affected / exposed	2 / 42 (4.76%)	9 / 47 (19.15%)	3 / 36 (8.33%)
occurrences (all)	5	11	3
Aphthous Stomatitis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 47 (2.13%)	3 / 36 (8.33%)
occurrences (all)	0	1	3
Constipation			
subjects affected / exposed	2 / 42 (4.76%)	5 / 47 (10.64%)	4 / 36 (11.11%)
occurrences (all)	2	6	4
Diarrhoea			
subjects affected / exposed	15 / 42 (35.71%)	18 / 47 (38.30%)	12 / 36 (33.33%)
occurrences (all)	18	33	18
Dry Mouth			
subjects affected / exposed	4 / 42 (9.52%)	3 / 47 (6.38%)	0 / 36 (0.00%)
occurrences (all)	4	3	0
Dyspepsia			

subjects affected / exposed	0 / 42 (0.00%)	6 / 47 (12.77%)	0 / 36 (0.00%)
occurrences (all)	0	8	0
Dysphagia			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	3 / 36 (8.33%)
occurrences (all)	1	1	3
Gastrooesophageal Reflux Disease			
subjects affected / exposed	2 / 42 (4.76%)	5 / 47 (10.64%)	1 / 36 (2.78%)
occurrences (all)	2	5	1
Haemorrhoids			
subjects affected / exposed	0 / 42 (0.00%)	3 / 47 (6.38%)	1 / 36 (2.78%)
occurrences (all)	0	3	1
Nausea			
subjects affected / exposed	13 / 42 (30.95%)	13 / 47 (27.66%)	7 / 36 (19.44%)
occurrences (all)	16	17	11
Stomatitis			
subjects affected / exposed	2 / 42 (4.76%)	1 / 47 (2.13%)	2 / 36 (5.56%)
occurrences (all)	2	1	2
Vomiting			
subjects affected / exposed	6 / 42 (14.29%)	9 / 47 (19.15%)	6 / 36 (16.67%)
occurrences (all)	6	15	9
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 42 (0.00%)	4 / 47 (8.51%)	0 / 36 (0.00%)
occurrences (all)	0	4	0
Ecchymosis			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	2 / 36 (5.56%)
occurrences (all)	1	1	3
Hyperhidrosis			
subjects affected / exposed	1 / 42 (2.38%)	1 / 47 (2.13%)	2 / 36 (5.56%)
occurrences (all)	2	2	2
Intertrigo			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences (all)	0	0	2
Night Sweats			
subjects affected / exposed	5 / 42 (11.90%)	2 / 47 (4.26%)	0 / 36 (0.00%)
occurrences (all)	5	2	0

Photosensitivity Reaction subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	2 / 36 (5.56%) 3
Pruritus subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3	6 / 47 (12.77%) 7	0 / 36 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	8 / 47 (17.02%) 10	2 / 36 (5.56%) 2
Rash Maculo-Papular subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	5 / 47 (10.64%) 5	2 / 36 (5.56%) 3
Renal and urinary disorders			
Renal Failure subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	1 / 36 (2.78%) 1
Urinary Retention subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	2 / 36 (5.56%) 3
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	8 / 47 (17.02%) 8	1 / 36 (2.78%) 1
Back Pain subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	5 / 47 (10.64%) 6	3 / 36 (8.33%) 3
Groin Pain subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	3 / 47 (6.38%) 3	1 / 36 (2.78%) 1
Muscle Spasms subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	1 / 47 (2.13%) 1	2 / 36 (5.56%) 2
Muscular Weakness subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 47 (0.00%) 0	2 / 36 (5.56%) 2
Musculoskeletal Pain			

subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	3 / 47 (6.38%) 3	5 / 36 (13.89%) 6
Myalgia subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	5 / 47 (10.64%) 5	2 / 36 (5.56%) 2
Pain In Extremity subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 5	3 / 47 (6.38%) 4	2 / 36 (5.56%) 2
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	7 / 47 (14.89%) 7	4 / 36 (11.11%) 5
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	3 / 47 (6.38%) 4	0 / 36 (0.00%) 0
Cystitis subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 47 (0.00%) 0	2 / 36 (5.56%) 2
Nasopharyngitis subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 4	2 / 47 (4.26%) 4	3 / 36 (8.33%) 4
Oral Herpes subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	4 / 47 (8.51%) 4	1 / 36 (2.78%) 1
Oropharyngeal Candidiasis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	2 / 36 (5.56%) 2
Pharyngitis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 47 (2.13%) 1	2 / 36 (5.56%) 3
Pneumonia subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	1 / 47 (2.13%) 1	3 / 36 (8.33%) 4
Pneumonia Fungal subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	2 / 36 (5.56%) 2

Respiratory Tract Infection subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 47 (0.00%) 0	2 / 36 (5.56%) 2
Rhinitis subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	2 / 47 (4.26%) 3	2 / 36 (5.56%) 2
Sinusitis subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	3 / 47 (6.38%) 4	1 / 36 (2.78%) 1
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4	9 / 47 (19.15%) 11	0 / 36 (0.00%) 0
Urinary Tract Infection subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	7 / 47 (14.89%) 14	2 / 36 (5.56%) 2
Metabolism and nutrition disorders			
Decreased Appetite subjects affected / exposed occurrences (all)	8 / 42 (19.05%) 8	10 / 47 (21.28%) 12	8 / 36 (22.22%) 9
Diabetes Mellitus subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 47 (0.00%) 0	2 / 36 (5.56%) 2
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 47 (2.13%) 1	2 / 36 (5.56%) 2
Hyperglycaemia subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 5	6 / 47 (12.77%) 10	1 / 36 (2.78%) 1
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	2 / 47 (4.26%) 2	3 / 36 (8.33%) 6
Hyperuricaemia subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	2 / 47 (4.26%) 2	2 / 36 (5.56%) 2
Hypocalcaemia			

subjects affected / exposed	2 / 42 (4.76%)	0 / 47 (0.00%)	3 / 36 (8.33%)
occurrences (all)	2	0	6
Hypoglycaemia			
subjects affected / exposed	2 / 42 (4.76%)	0 / 47 (0.00%)	2 / 36 (5.56%)
occurrences (all)	2	0	2
Hypokalaemia			
subjects affected / exposed	4 / 42 (9.52%)	2 / 47 (4.26%)	3 / 36 (8.33%)
occurrences (all)	6	3	12
Hypomagnesaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 47 (0.00%)	3 / 36 (8.33%)
occurrences (all)	0	0	4
Hypophosphataemia			
subjects affected / exposed	2 / 42 (4.76%)	3 / 47 (6.38%)	5 / 36 (13.89%)
occurrences (all)	2	4	14

Non-serious adverse events	SAR245409: R/R DLBCL Subjects		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	38 / 42 (90.48%)		
Vascular disorders			
Deep Vein Thrombosis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Hypotension			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Chills			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	4		
Fatigue			

subjects affected / exposed	15 / 42 (35.71%)		
occurrences (all)	21		
General Physical Health Deterioration			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Influenza Like Illness			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Non-Cardiac Chest Pain			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Oedema Peripheral			
subjects affected / exposed	8 / 42 (19.05%)		
occurrences (all)	9		
Pyrexia			
subjects affected / exposed	7 / 42 (16.67%)		
occurrences (all)	8		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	10 / 42 (23.81%)		
occurrences (all)	14		
Dysphonia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	6 / 42 (14.29%)		
occurrences (all)	6		
Dyspnoea Exertional			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Epistaxis			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Lung Infiltration			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Oropharyngeal Pain			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Pleural Effusion			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Productive Cough			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Wheezing			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	7 / 42 (16.67%)		
occurrences (all)	8		
Amylase Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Aspartate Aminotransferase Increased			

subjects affected / exposed	7 / 42 (16.67%)		
occurrences (all)	7		
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Blood Creatinine Increased			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	4		
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
C-Reactive Protein Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Gamma-Glutamyltransferase Increased			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Platelet Count Decreased			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Weight Decreased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
White Blood Cell Count Decreased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Tendon Rupture			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		

Nervous system disorders Dizziness subjects affected / exposed occurrences (all) Dysgeusia subjects affected / exposed occurrences (all) Headache subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1 3 / 42 (7.14%) 3 5 / 42 (11.90%) 7		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) Leukocytosis subjects affected / exposed occurrences (all) Leukopenia subjects affected / exposed occurrences (all) Lymphopenia subjects affected / exposed occurrences (all) Neutropenia subjects affected / exposed occurrences (all) Thrombocytopenia subjects affected / exposed occurrences (all)	9 / 42 (21.43%) 12 0 / 42 (0.00%) 0 1 / 42 (2.38%) 1 0 / 42 (0.00%) 0 4 / 42 (9.52%) 4 6 / 42 (14.29%) 7		
Gastrointestinal disorders Abdominal Pain subjects affected / exposed occurrences (all) Abdominal Pain Upper subjects affected / exposed occurrences (all) Aphthous Stomatitis	2 / 42 (4.76%) 2 2 / 42 (4.76%) 2		

subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	5 / 42 (11.90%)		
occurrences (all)	5		
Diarrhoea			
subjects affected / exposed	13 / 42 (30.95%)		
occurrences (all)	18		
Dry Mouth			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Dyspepsia			
subjects affected / exposed	5 / 42 (11.90%)		
occurrences (all)	5		
Dysphagia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Gastrooesophageal Reflux Disease			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Haemorrhoids			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	11 / 42 (26.19%)		
occurrences (all)	12		
Stomatitis			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Vomiting			
subjects affected / exposed	8 / 42 (19.05%)		
occurrences (all)	10		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		

Ecchymosis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Intertrigo			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Night Sweats			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Photosensitivity Reaction			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	4		
Rash Maculo-Papular			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	6		
Renal and urinary disorders			
Renal Failure			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Urinary Retention			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Back Pain			

subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Groin Pain			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Muscle Spasms			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	2		
Muscular Weakness			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Musculoskeletal Pain			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Pain In Extremity			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Infections and infestations			
Bronchitis			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Conjunctivitis			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Oral Herpes			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		

Oropharyngeal Candidiasis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Pharyngitis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Pneumonia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Pneumonia Fungal subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Respiratory Tract Infection subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Rhinitis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Sinusitis subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 6		
Urinary Tract Infection subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Metabolism and nutrition disorders			
Decreased Appetite subjects affected / exposed occurrences (all)	8 / 42 (19.05%) 10		
Diabetes Mellitus subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Hypercalcaemia			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Hyperkalaemia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Hyperuricaemia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Hypocalcaemia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Hypoglycaemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	11		
Hypomagnesaemia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	2		
Hypophosphataemia			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	6		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 October 2011	It included following changes: -Clarification on disease assessment requirements and definitions. - Description of safety review process by the Sponsor and clarification on data collection conventions. - A consultation with a geriatrician during screening was recommended by French Agency for the Safety of Health Products (AFSSAPS) to ensure the eligibility of elderly subjects to participate. - Change in frequency of on-study ophthalmologic assessment, fasting glucose and urinalysis. - Exclusion criteria was modified to allow enrollment of subjects with chronic, well controlled Grade 2 atrial fibrillation. - Addition of collection of plasma samples to assess chemokines variation during study treatment and addition of whole blood sample to evaluate whether BH3 profiling could be used as a biomarker to predict clinical response to SAR245409. - Hair follicle collection was no longer required for pharmacodynamic assessments. - The requirement for buccal mucosal swabs for DNA testing (pharmacogenomics) in subjects with CLL/SLL was changed to collection of saliva samples to ensure adequate yield of normal cells.
21 June 2012	It included following changes: - Addition of a cohort of subjects with R/R diffuse large B-cell lymphoma. - Collection of an additional saliva sample during screening for matching normal DNA. - The definition and reporting of symptomatic / non symptomatic events of overdose had been harmonized across all studies with SAR245409.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported